CRRT์—์„œ ๊ฐ„ํ—์  ํ˜ˆ์•กํˆฌ์„์œผ๋กœ ์ „ํ™˜ / CRRT to intermittent hemodialysis transition

์ •์˜

AKI/ICU ํ™˜์ž์—์„œ ํ˜ˆ์—ญํ•™์ ์œผ๋กœ ๋ถˆ์•ˆ์ •ํ•  ๋•Œ CRRT๋กœ ์‹œ์ž‘ํ•œ ๋’ค, ์•ˆ์ •ํ™”๋˜๋ฉด IHD/HD ๋˜๋Š” SLED/PIRRT๋กœ ๋‹จ๊ณ„์ ์œผ๋กœ ์ „ํ™˜ํ•˜๋Š” ์น˜๋ฃŒ ํ๋ฆ„.

์ž„์ƒ ํ•ต์‹ฌ

CRRT์—์„œ HD๋กœ ๋ฐ”๊พธ๋Š” ๊ฒƒ์€ ๋ฐ˜๋“œ์‹œ ์‹ ์žฅ ๊ธฐ๋Šฅ ํšŒ๋ณต์„ ๋œปํ•˜์ง€ ์•Š๋Š”๋‹ค. ํ•ต์‹ฌ ์˜๋ฏธ๋Š” ํ™˜์ž๊ฐ€ ๋น ๋ฅธ intermittent dialysis์™€ ultrafiltration์„ ๊ฒฌ๋”œ ๋งŒํผ ์•ˆ์ •ํ•ด์กŒ๋‹ค๋Š” ๊ฒƒ์ด๋‹ค. ์ „ํ™˜ ์ „์—๋Š” vasopressor ์š”๊ตฌ๋Ÿ‰์ด ์—†๊ฑฐ๋‚˜ ๋งค์šฐ ๋‚ฎ๊ณ  ์•ˆ์ •์ ์ด์–ด์•ผ ํ•œ๋‹ค. MAP/ํ˜ˆ์••์ด ์•ˆ์ •์ ์ด๊ณ , ๊ธ‰๊ฒฉํ•œ fluid removal ์—†์ด๋„ ๋ฒ„ํ‹ธ ์ˆ˜ ์žˆ์–ด์•ผ ํ•œ๋‹ค. ์‚ฐ์ฆ, ๊ณ ์นผ๋ฅจํ˜ˆ์ฆ, uremia๊ฐ€ ์กฐ์ ˆ๋˜๊ณ  ICU-level continuous therapy ํ•„์š”์„ฑ์ด ์ค„์–ด์•ผ ํ•œ๋‹ค.

์ง„๋‹จ

์ „ํ™˜ ๊ฐ€๋Šฅ์„ฑ์€ ํ˜ˆ์••, MAP, vasopressor dose, lactate trend, daily volume balance, K/acid-base/uremia ์กฐ์ ˆ ์ƒํƒœ๋กœ ํ‰๊ฐ€ํ•œ๋‹ค. Neurologic osmotic shift ์šฐ๋ ค๊ฐ€ ํฌ๋ฉด ๋น ๋ฅธ IHD ์ „ํ™˜์„ ๋” ์กฐ์‹ฌํ•œ๋‹ค. ์ฒซ IHD ์ค‘ hypotension์ด ์ƒ๊ธฐ๋ฉด ์•„์ง intermittent therapy๋ฅผ ๊ฒฌ๋””์ง€ ๋ชปํ•œ๋‹ค๋Š” ์‹ ํ˜ธ์ผ ์ˆ˜ ์žˆ๋‹ค.

์น˜๋ฃŒ

์ผ๋ฐ˜ ํ๋ฆ„์€ shock/pressor/ARDS/oliguria ์ƒํƒœ์—์„œ CRRT๋ฅผ ์‹œํ–‰ํ•˜๊ณ , pressor๊ฐ€ ์ค„๊ณ  fluid status๊ฐ€ ์•ˆ์ •๋˜๋ฉด CRRT dose๋‚˜ net UF๋ฅผ ์™„ํ™”ํ•œ๋‹ค. 24์‹œ๊ฐ„ ์ด์ƒ ์•ˆ์ •์ ์ด๋ฉด SLED/PIRRT ๋˜๋Š” IHD trial์„ ๊ณ ๋ คํ•œ๋‹ค. IHD ์ค‘ hypotension ์—†์ด lab๊ณผ volume์ด ์กฐ์ ˆ๋˜๋ฉด HD๋ฅผ ์œ ์ง€ํ•œ๋‹ค. Urine output์ด ํšŒ๋ณต๋˜๊ณ  Cr/BUN trend๊ฐ€ ์•ˆ์ •๋˜๋ฉด RRT ์ค‘๋‹จ trial์„ ๊ณ ๋ คํ•œ๋‹ค. Aggressive UF๋Š” ํ”ผํ•˜๊ณ , pressor ์žฌ์ฆ๊ฐ€ยทlactate ์ƒ์ŠนยทMAP drop์ด ์žˆ์œผ๋ฉด CRRT ์žฌ์ „ํ™˜์„ ๊ณ ๋ คํ•œ๋‹ค.

์ถœ์ฒ˜

KDIGO AKI guideline.

๐ŸŒฑ ์ถœ์ฒ˜ raw


๋ณธ ๋ฌธ์„œ๋Š” ํ•™์Šตยท์ฐธ๊ณ ์šฉ์ด๋ฉฐ ์‹ค์ œ ์ง„๋ฃŒ ๊ฒฐ์ •์€ ์ž„์ƒ์˜์˜ ํŒ๋‹จ์ž…๋‹ˆ๋‹ค.